| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CALC | Common Stock | Purchase | $901K | +243K | +34.6% | $3.70 | 947K | Jan 23, 2024 | By Sanderling Venture Partners VI, LP | F1, F2 |
| transaction | CALC | Common Stock | Purchase | $536K | +145K | +24.83% | $3.70 | 727K | Jan 23, 2024 | By Sanderling Venture Partners VI Co-Investment Fund, L.P. | F1, F3 |
| transaction | CALC | Common Stock | Purchase | $720K | +194K | +80.8% | $3.70 | 435K | Jan 23, 2024 | By Sanderling Ventures VII, L.P. | F1, F4 |
| transaction | CALC | Common Stock | Purchase | $189K | +51K | +80.71% | $3.70 | 114K | Jan 23, 2024 | By Sanderling Ventures VII (Canada), L.P. | F1, F5 |
| transaction | CALC | Common Stock | Purchase | $48.8K | +13.2K | +91.4% | $3.70 | 27.6K | Jan 23, 2024 | By Sanderling Ventures VII Annex Fund, L.P. | F1, F4 |
| transaction | CALC | Common Stock | Purchase | $14.5K | +3.92K | +22.17% | $3.70 | 21.6K | Jan 23, 2024 | By Sanderling Ventures Management VI | F1, F3 |
| transaction | CALC | Common Stock | Purchase | $106K | +28.7K | +1856.85% | $3.70 | 30.3K | Jan 23, 2024 | By Sanderling Ventures Management VII | F1, F5 |
| holding | CALC | Common Stock | 11.7K | Jan 23, 2024 | Direct | ||||||
| holding | CALC | Common Stock | 8.18K | Jan 23, 2024 | By Golden Triangle Ventures, LLC | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CALC | Warrant | Purchase | $15.2K | +122K | $0.13* | 122K | Jan 23, 2024 | Common Stock | 122K | $5.36 | By Sanderling Venture Partners VI, LP | F1, F3, F7 | |
| transaction | CALC | Warrant | Purchase | $15.2K | +122K | $0.13* | 122K | Jan 23, 2024 | Common Stock | 122K | $7.15 | By Sanderling Venture Partners VI, LP | F1, F3, F8 | |
| transaction | CALC | Warrant | Purchase | $9.04K | +72.3K | $0.13* | 72.3K | Jan 23, 2024 | Common Stock | 72.3K | $5.36 | By Sanderling Venture Partners VI Co-Investment Fund, L.P. | F1, F3, F7 | |
| transaction | CALC | Warrant | Purchase | $9.04K | +72.3K | $0.13* | 72.3K | Jan 23, 2024 | Common Stock | 72.3K | $7.15 | By Sanderling Venture Partners VI Co-Investment Fund, L.P. | F1, F3, F8 | |
| transaction | CALC | Warrant | Purchase | $12.2K | +97.2K | $0.13* | 97.2K | Jan 23, 2024 | Common Stock | 97.2K | $5.36 | By Sanderling Ventures VII, L.P. | F1, F5, F7 | |
| transaction | CALC | Warrant | Purchase | $12.2K | +97.2K | $0.13* | 97.2K | Jan 23, 2024 | Common Stock | 97.2K | $7.15 | By Sanderling Ventures VII, L.P. | F1, F5, F8 | |
| transaction | CALC | Warrant | Purchase | $3.19K | +25.5K | $0.13* | 25.5K | Jan 23, 2024 | Common Stock | 25.5K | $5.36 | By Sanderling Ventures VII (Canada), L.P. | F1, F5, F7 | |
| transaction | CALC | Warrant | Purchase | $3.19K | +25.5K | $0.13* | 25.5K | Jan 23, 2024 | Common Stock | 25.5K | $7.15 | By Sanderling Ventures VII (Canada), L.P. | F1, F5, F8 | |
| transaction | CALC | Warrant | Purchase | $824 | +6.59K | $0.13* | 6.59K | Jan 23, 2024 | Common Stock | 6.59K | $5.36 | By Sanderling Ventures VII Annex Fund, L.P. | F1, F5, F7 | |
| transaction | CALC | Warrant | Purchase | $824 | +6.59K | $0.13* | 6.59K | Jan 23, 2024 | Common Stock | 6.59K | $7.15 | By Sanderling Ventures VII Annex Fund, L.P. | F1, F5, F8 | |
| transaction | CALC | Warrant | Purchase | $245 | +1.96K | $0.13* | 1.96K | Jan 23, 2024 | Common Stock | 1.96K | $5.36 | By Sanderling Ventures Management VI | F1, F3, F7 | |
| transaction | CALC | Warrant | Purchase | $245 | +1.96K | $0.13* | 1.96K | Jan 23, 2024 | Common Stock | 1.96K | $7.15 | By Sanderling Ventures Management VI | F1, F3, F8 | |
| transaction | CALC | Warrant | Purchase | $1.8K | +14.4K | $0.13* | 14.4K | Jan 23, 2024 | Common Stock | 14.4K | $5.36 | By Sanderling Ventures Management VII | F1, F5, F7 | |
| transaction | CALC | Warrant | Purchase | $1.8K | +14.4K | $0.13* | 14.4K | Jan 23, 2024 | Common Stock | 14.4K | $7.15 | By Sanderling Ventures Management VII | F1, F5, F8 |
| Id | Content |
|---|---|
| F1 | The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. |
| F2 | The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| F3 | The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| F4 | The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| F5 | The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| F6 | The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| F7 | The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| F8 | The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |